Who is sponsoring NCT05247268?

NCT05247268 is sponsored by Fudan University.

What drugs are being tested in NCT05247268?

Interventions in NCT05247268: Megestrol Acetate 160 MG Oral Tablet, Medroxyprogesterone Acetate 500 MG, Triprorelin Acetate, Letrozole 2.5mg.

What condition does NCT05247268 study?

NCT05247268 studies Endometrial Neoplasm Malignant Stage I.

Is NCT05247268 still recruiting?

NCT05247268 is currently recruiting now. Last updated 6 April 2025.

Last reviewed 2025-04-06 · How we verify

NCT05247268

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Recruiting now Phase 2 Last updated 6 April 2025

What this trial tests

Phase 2 trial testing Megestrol Acetate 160 MG Oral Tablet in Endometrial Neoplasm Malignant Stage I in 104 participants. Currently enrolling.

Timeline

11 March 2022

Primary endpoint
10 March 2027

10 September 2027

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	104
Start date	11 March 2022
Primary completion	10 March 2027
Estimated completion	10 September 2027
Sites	1 location across China

Drugs / interventions tested

Megestrol Acetate 160 MG Oral Tablet
Medroxyprogesterone Acetate 500 MG — full drug profile →
Triprorelin Acetate — full drug profile →
Letrozole 2.5mg (letrozole-2-5mg) — full drug profile →

Conditions studied

Endometrial Neoplasm Malignant Stage I — all drugs for Endometrial Neoplasm Malignant Stage I →

Sponsor

Fudan University

Who can join

Adults 18 to 45, female only, with Endometrial Neoplasm Malignant Stage I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA/MPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer.
Adjei NN, Bowen MB, Wilke RN, Yates MS, et al · · 2024 · PMID 39361076 · DOI 10.1007/s11912-024-01603-9

Verify or expand the search:

Other trials of Megestrol Acetate 160 MG Oral Tablet

Trials testing the same drug.

NCT05316493 — Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia · Phase 2, PHASE3 · recruiting
NCT05316467 — Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma · Phase 2, PHASE3 · recruiting

Other recruiting trials for Endometrial Neoplasm Malignant Stage I

Currently open trials in the same condition.

NCT05945407 — Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer · NA · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05247268 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 6 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05247268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing